Daratumumab Monotherapy versus Bortezomib-Based Regimens in frail patients with Biopsy-Proven Renal AL Amyloidosis
Clicks: 1
ID: 314240
2026
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This
article has not been analysed, so there is no overall score —
reader engagement is measured and shown alongside.
Reader Engagement
0.0
/100
1 views
0 readers
AI Quality Assessment
Not analyzed
Readership in this journal
Ranked #77 of 98 articles by views in nephrology dialysis transplantation
Most read
Least read
Bar heights use a square-root scale.
Mint this article as an NFT
Not yet mintedCreate a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.
5
SUSD
one-off · no wallet required
Abstract
BACKGROUND: Bortezomib-based regimens have long represented the standard option for systemic AL amyloidosis, whereas daratumumab has recently emerged as a promising alternative. We compared two consecutive single-center cohorts of frail, non-transplant-eligible patients treated with either bortezomib-based therapy or daratumumab monotherapy, assessing clinical and renal outcomes. METHODS: Thirty-one patients with renal AL amyloidosis were included: 17 received bortezomib-based regimens (historical cohort) and 14 received daratumumab monotherapy (prospective cohort). All had biopsy-confirmed renal amyloid deposition and were transplan-ineligible. Hematologic and organ responses followed International Society of Amyloidosis criteria. RESULTS: Baseline characteristics were similar between cohorts. Hematologic response rates were 57.1% with bortezomib versus 92.8% with daratumumab (p = 0.03), with complete responses in 28.6% and 57.1%, respectively. Renal response occurred in 35% of bortezomib-treated patients versus 71.4% with daratumumab (p = 0.04). Proteinuria declined by 76% in bortezomib responders and 72% in daratumumab responders, with stable creatinine in both groups. Among patients achieving dual hematologic and renal responses, 12-month survival was 100% in the daratumumab cohort versus 71% in the historical group. At last follow-up, renal survival was 67% versus 86%, and overall survival 47% versus 79% (p = 0.08). Major infections occurred in 18% and 14%, respectively. Repeat biopsies showed stabilization or regression of amyloid in 62% of daratumumab-treated versus 20% of historical cases. CONCLUSIONS: In frail, ASCT-ineligible patients with biopsy-proven renal AL amyloidosis, daratumumab monotherapy yielded higher hematologic and renal response rates compared with bortezomib-based regimens. These findings support early anti-CD38 therapy as a potential strategy to improve renal preservation and survival, warranting confirmation in multicenter trials.
| Reference Key |
openalex_W7161858523
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | Roccatello Dario, Sciascia Savino, Antonella Barreca, Rabajoli Gianluca, Del Vecchio Giulio, Rossi Daniela, Rubini Elena, Fenoglio Roberta |
| Journal | nephrology dialysis transplantation |
| Year | 2026 |
| DOI |
10.1093/ndt/gfag117
|
| URL | |
| Keywords | Keywords not found |
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.